Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.

The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables.

This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain.

Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32-81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7-41.0) and the median time to CR was 10.9 months (IQR, 7.2-19.3). After a median follow-up of 8 years (range, 3-13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2-99.4). The tolerance and safety profile of sunitinib was consistent with previous reports.

Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years.

gov: NCT03916458.

Clinical genitourinary cancer. 2022 Dec 05 [Epub ahead of print]

Guillermo de Velasco, Teresa Alonso-Gordoa, Alejo Rodríguez-Vida, Georgia Anguera, Marc Campayo, Álvaro Pinto, Esther Martínez Ortega, Enrique Gallardo, Natalia Fernández Núñez, Iciar García-Carbonero, Oscar Reig, María José Méndez-Vidal, Ovidio Fernández-Calvo, Natalia Vidal Cassinello, Dolores Torregrosa, Ana López-Martín, Adriana Rosero, Patricia G Valiente, Carmen Garcías de España, Miguel A Climent, Montserrat Domenech Santasusana, Ángel Rodríguez Sánchez, Isabel Chirivella González, Ruth Afonso, Xavier García Del Muro, Javier Casinello, Eva M Fernández-Parra, Lourdes García Sánchez, Javier Afonso, Susana Hernando Polo, Úrsula Asensio

Department of Medical Oncology, Madrid, Spain. Electronic address: ., Department of Medical Oncology and Department of Genitourinary, Germ cell and Endocrine Tumors, Ramón y Cajal University Hospital and Ramón y Cajal Health Research Institute (IRYCIS), Madrid, Spain., Department of Medical Oncology, Hospital del Mar-CIBERONC, IMIM Research Institute, Barcelona, Spain., Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Department of Medical Oncology, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Department of Medical Oncology, University Hospital La Paz, Madrid, Spain., Department of Medical Oncology, University Hospital of Jaén, Jaén, Spain., Department of Medical Oncology, University Hospital Parc Taulí, Institut d'Investigació i Innovació Parc Taulí, Sabadell, Spain., Department of Medical Oncology, University Hospital Lucus Augusti, Lugo, Spain., Department of Medical Oncology, University Hospital of Toledo, Toledo, Spain., Department of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors Group (IDIBAPS), Barcelona, Spain., Department of Medical Oncology, University Hospital Reina Sofía, Maimónides Institute for Biomedical research of Córdoba (IMIBIC), Córdoba, Spain., Department of Medical Oncology, University Hospital of Ourense, Ourense, Spain., Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Department of Medical Oncology, University Hospital Dr. Peset, Valencia, Spain., Medical Oncology Department, University Hospital Severo Ochoa, Madrid, Spain., Department of Medical Oncology, University Hospital Infanta Cristina, Parla, Madrid, Spain., Department of Medical Oncology, University Hospital Marqués de Valdecilla, Santander, Spain., Department of Medical Oncology, University Hospital Son Espases, Palma de Mallorca, Spain., Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Department of Medical Oncology, Hospital Althaia, Manresa, Spain., Department of Medical Oncology, University Hospital of León, León, Spain., Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA, University of Valencia, Valencia, Spain., Department of Medical Oncology, University Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Genitourinary Cancer and Sarcoma Unit, Institut Català d'Oncologia, Hospitalet, Barcelona, Spain., Department of Medical Oncology, University Hospital of Guadalajara, Guadalajara, Spain., Department of Medical Oncology, University Hospital Valme, Sevilla, Spain., Department of Medical Oncology, University Hospital of Segovia, Segovia, Spain., Department of Medical Oncology, University Hospital of Ferrol, A Coruña, Spain., Department of Medical Oncology, University Hospital Fundación Alcorcón, Madrid, Spain., Medical Department, Pfizer Oncology, Madrid, Spain.